MX2010001244A - Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same. - Google Patents

Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same.

Info

Publication number
MX2010001244A
MX2010001244A MX2010001244A MX2010001244A MX2010001244A MX 2010001244 A MX2010001244 A MX 2010001244A MX 2010001244 A MX2010001244 A MX 2010001244A MX 2010001244 A MX2010001244 A MX 2010001244A MX 2010001244 A MX2010001244 A MX 2010001244A
Authority
MX
Mexico
Prior art keywords
methods
compositions
arylamino
inhibitors
mek
Prior art date
Application number
MX2010001244A
Other languages
Spanish (es)
Inventor
Jean-Michel Vernier
Colin Edward Rowlings
Jean-Luc Girardet
Stuart Dimock
Barry Quart
Jeffrey N Miner
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010001244(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of MX2010001244A publication Critical patent/MX2010001244A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also concerns methods of making the compunds and compositions described herein.
MX2010001244A 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same. MX2010001244A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (1)

Publication Number Publication Date
MX2010001244A true MX2010001244A (en) 2010-08-31

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001244A MX2010001244A (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same.

Country Status (23)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20150091434A (en)
CN (2) CN103479604B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA020624B1 (en)
EC (1) ECSP109910A (en)
HK (1) HK1147396A1 (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
KR20110014149A (en) * 2008-04-14 2011-02-10 아디아 바이오사이언스즈 인크. Compositions and methods for preparing and using same
ES2706875T3 (en) * 2008-09-09 2019-04-01 Hoffmann La Roche Acrylsulfonamide polymorphs
CN105079805A (en) 2008-09-26 2015-11-25 昂考梅德药品有限公司 Frizzled-binding agents and uses thereof
JP5767122B2 (en) * 2009-03-11 2015-08-19 アルデア バイオサイエンシズ，インコーポレイティド Combination medicine comprising RDEA119 / BAY869766 for the treatment of certain cancers
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
WO2011047055A2 (en) 2009-10-13 2011-04-21 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
JP2013508318A (en) * 2009-10-21 2013-03-07 バイエル・ファルマ・アクチェンゲゼルシャフト Substituted benzosulfonamide derivatives
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
MX2013012183A (en) * 2011-04-28 2014-05-27 Sloan Kettering Inst Cancer Hsp90 combination therapy.
UA113850C2 (en) * 2011-05-27 2017-03-27 CHIRAL SYNTHESIS N- {3,4-DIFLUTOR-2 - $ (2-FLUORO-4-IODPHENYL) AMINO] -6-METHOXYPHENYL} -1- $ 2,3-DYHYDROXYPROPYL] CYCLOPROPANSPANE
JP2015502958A (en) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド Combination therapy for the treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2013178581A1 (en) * 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
KR20150015021A (en) * 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 Crystalline forms of a bruton's tyrosine kinase inhibitor
AR099630A1 (en) * 2012-10-19 2016-08-10 Novartis Ag PREPARATION OF A MEK INHIBITOR AND FORMULATION THAT UNDERSTANDS
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US11197896B2 (en) * 2014-08-25 2021-12-14 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
RU2017133990A (en) 2015-03-03 2019-04-05 Фармасайкликс Элэлси PHARMACEUTICAL MEDICINAL FORMS OF BRUTON TYROSINKINASE INHIBITOR
BR112019026483A2 (en) * 2017-06-16 2020-07-14 Beta Pharma, Inc. pharmaceutical formulation of n- (2- (2- (dimethylamine) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) acrylamide and its salts
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
ATE172717T1 (en) * 1992-08-25 1998-11-15 Searle & Co HYDROXYETHYLAMINOSULFONAMIDES USABLE AS INHIBITORS OF RETROVIRAL PROTEASES
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
JP2002534515A (en) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1-heterocyclic-substituted diarylamines
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
KR20040062546A (en) * 2001-09-24 2004-07-07 제시 엘. 에스. 에이유 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
JP2006502117A (en) * 2002-07-17 2006-01-19 タイタン ファーマシューティカルズ インコーポレイテッド Combination of chemotherapeutic drugs to increase antitumor activity
DK1545553T3 (en) * 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antitumor drugs
US8309133B2 (en) * 2005-04-12 2012-11-13 Alkermes Pharma Ireland Limited Nanoparticulate quinazoline derivative formulations
CN101198582A (en) * 2005-04-22 2008-06-11 橘生药品工业株式会社 Polymorphic crystal of 4'-{2-[ (1s, 2r) - 2- hydroxy -2- (4-hydroxyphenyl) -1- methylethylamino] ethoxy} - 3 - isopropyl-3', 5' -dimethylbiphenyl - 4 - carboxylic acid hydrochloride
PT1912636E (en) * 2005-07-21 2014-07-24 Ardea Biosciences Inc N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd New crystal of piperacillin sodium-1 hydrate and method for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
AU2008282338B2 (en) 2015-02-12
PH12015501914A1 (en) 2017-07-31
JP6309880B2 (en) 2018-04-11
IL203296A (en) 2017-06-29
BRPI0815659A2 (en) 2014-09-30
CN101808516A (en) 2010-08-18
CN103479604A (en) 2014-01-01
CR11244A (en) 2010-05-20
KR20100092424A (en) 2010-08-20
WO2009018233A1 (en) 2009-02-05
NZ582929A (en) 2012-03-30
KR20140098185A (en) 2014-08-07
SV2010003469A (en) 2010-04-30
CO6470808A2 (en) 2012-06-29
ECSP109910A (en) 2010-04-30
EP2184984A4 (en) 2013-07-24
CA2693390A1 (en) 2009-02-05
CA2693390C (en) 2017-01-17
EA201000268A1 (en) 2010-08-30
KR20150091434A (en) 2015-08-10
CN103479604B (en) 2016-08-10
HN2010000203A (en) 2012-11-19
JP2017125021A (en) 2017-07-20
EP2184984A1 (en) 2010-05-19
AU2008282338A1 (en) 2009-02-05
JP2015078199A (en) 2015-04-23
AU2015200390B2 (en) 2017-02-23
MA31881B1 (en) 2010-12-01
CN101808516B (en) 2013-08-28
DOP2010000045A (en) 2010-10-31
JP2010535232A (en) 2010-11-18
TN2010000049A1 (en) 2011-09-26
AP2010005134A0 (en) 2010-02-28
EA020624B1 (en) 2014-12-30
HK1147396A1 (en) 2011-08-12
EA032294B1 (en) 2019-05-31
EA201400552A1 (en) 2014-09-30
AP2817A (en) 2013-12-31

Similar Documents

Publication Publication Date Title
PH12015501914A1 (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA99731C2 (en) Crystalline polymorphic forms of n-(2-arylamino) aryl sulfonamides as inhibitors of mek, a composition (variants) and use
NO2023022I1 (en) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
MX2009012168A (en) Pyrrolopyridine derivatives and their use as bace inhibitors.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
MX2012007273A (en) Pteridinones as inhibitors of polo - like kinase.
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
MX2021015935A (en) Salt forms of bempedoic acid and methods for using the same.
TW200734311A (en) New compounds
WO2010053583A3 (en) Small molecule cd4 mimetics and uses thereof
MX2009000884A (en) Pyridizinone derivatives.
TW200640883A (en) Compounds for the treatment of proliferative disorders
CY1109348T1 (en) DIHYDRO-SULFUR-PYRIMIDES FOR THE TREATMENT OF INFLAMMATORY PATIENTS
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TW200613243A (en) Novel compounds
NZ590334A (en) ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
CY1122201T1 (en) BENZODIOXOLE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
EA201001687A1 (en) IMIDAZOPIRIDINE DERIVATIVES AS AN INHIBITOR ACTIVATIVE-LIKE RECEPTOR KINASE (ALK-4 OR ALK-5)
MY194116A (en) Pharmaceutical compounds
TW200716570A (en) Compounds for the treatment of proliferative disorders
SE0400284D0 (en) Novel compounds
WO2010145197A8 (en) Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors
WO2007143523A3 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
WO2010129918A8 (en) Triptolide prodrugs

Legal Events

Date Code Title Description
FG Grant or registration